香港交易及結算所有限公司及香港聯合交易所有限公司對本文件的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本文件全 部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 (於開曼群島註冊成立之有限公司) (股份代號：0775) 二零二四年中期業績 二零二四年中期業績 截至二零二四年六月三十日止六個月，長江生命科技集團有限公司（「長江生命 科技」或「公司」）錄得未經審核股東應佔溢利約港幣一百萬元，較去年同期下 跌百分之九十七（港幣三千五百九十萬元）。然而，未扣除財務成本之稅前溢利 實為港幣一億七千四百五十萬元，惟當中大部分被港幣一億六千九百五十萬元之 財務成本所抵銷。 董事會宣佈不派發二零二四年度中期股息（二零二三年：無）。 結算日後事項 長江生命科技於結算日後公佈，出售位於澳洲新南威爾士省瑞福利納（Riverina） 地區的 Balranald 葡萄園土地及用水許可證。瑞福利納地區屬內陸葡萄酒產區， 由於葡萄出口下降，當中尤以出口至中國為甚，導致葡萄供應過剩，業務因而受 影響。交易完成後，本公司預期將錄得約八百二十萬澳元（相等於約 港幣四千二百三十萬元）之出售收益。 醫 ...

（於開曼群島註冊成立的有限公司） （股份代號：0775） 提升 健康生活 2023 年報 | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------|-------|-------|-----------------------------------------------------------------------------------------------------------|-------|-------|-------|----------------------------------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 長江生命科技 | 簡介 | | | | | | | | 長江生命科技集團有限公司於香港聯合交易所有限公司上市。 本著提升人類生活質素之使命，長江生命科技從事產品之 | | | | | | | | | 研發、製造、商品化、推廣、銷售及投資，涉及的項目和 ...

Financial Performance - For the fiscal year ending December 31, 2023, the company reported a profit attributable to shareholders of HKD 17.3 million, a decrease of 87% compared to HKD 132 million in 2022[2] - The increase in financial costs amounted to HKD 159.3 million, significantly impacting profitability despite a pre-tax profit growth of HKD 23.1 million[2] - The group's total revenue for the year ended December 31, 2023, was HKD 5,322.7 million, a slight increase from HKD 5,275.6 million in 2022, with a cost of sales of HKD 3,685.5 million[16] - The net profit for the year was HKD 17.25 million, a significant decrease from HKD 131.95 million in the previous year, resulting in a basic earnings per share of HKD 0.18 compared to HKD 1.37 in 2022[16] - Total revenue for 2023 was HKD 5,322,733,000, a slight increase from HKD 5,275,590,000 in 2022, representing a growth of 0.89%[33] - The company reported a pre-tax profit of HKD 68,584 for 2023, down from HKD 204,864 in 2022, indicating a decline of 66.54%[42] - Net profit for 2023 was HKD 17,250, a significant decrease from HKD 131,952 in 2022, reflecting a decline of 87.00%[42] Revenue Contributions - The healthcare product business contributed a profit of HKD 283 million, an increase of 8% from the previous year[6] - The agricultural-related business recorded a profit contribution of HKD 350 million, growing by 4% compared to 2022[8] - Revenue from agricultural-related business decreased to HKD 1,913,356,000 in 2023 from HKD 2,005,001,000 in 2022, a decline of 4.6%[33] - Human health business revenue increased to HKD 3,242,902,000 in 2023, up from HKD 3,097,090,000 in 2022, reflecting a growth of 4.7%[33] - Agricultural business revenue for 2023 was HKD 2,078,664, a decrease of 4.55% from HKD 2,177,681 in 2022[42] - Human health business revenue for 2023 was HKD 3,242,902, an increase of 4.69% from HKD 3,097,090 in 2022[42] Assets and Liabilities - The total assets of the group as of December 31, 2023, were approximately HKD 11,247.4 million, with total liabilities amounting to HKD 5,058.1 million, leading to a net asset value of HKD 4,189.3 million[11] - The group maintained a net debt to total equity ratio of approximately 53.18% as of December 31, 2023[11] - Non-current liabilities increased significantly to HKD 4,957,596 thousand in 2023 from HKD 3,048,837 thousand in 2022, representing a growth of approximately 62.5%[21] - Total equity for the company stood at HKD 4,189,253 thousand in 2023, slightly up from HKD 4,155,450 thousand in 2022, indicating a marginal increase of about 0.8%[22] - The company's total assets net value was reported at HKD 4,189,253 thousand, showing stability compared to the previous year's figure of HKD 4,155,450 thousand[22] - Deferred tax liabilities decreased slightly from HKD 446,251 thousand in 2022 to HKD 436,381 thousand in 2023, indicating a reduction of about 2.0%[21] - The company’s bank borrowings rose to HKD 4,272,947 thousand in 2023 from HKD 2,374,000 thousand in 2022, representing an increase of approximately 79.9%[21] Research and Development - Research and development expenses for the year were approximately HKD 145.9 million, reflecting the company's commitment to innovation[12] - The company is focusing on the development of therapeutic cancer vaccines, with seviprotimut-L in the final research phase for melanoma patients[4] - The company is actively developing Halneuron® for alleviating cancer-related pain, with Phase II B clinical trials ongoing in South Korea and the United States[4] - The company is investing strategically in liquid biopsy diagnostic research to provide non-invasive and cost-effective cancer detection solutions[5] - The company plans to initiate the third phase of clinical trials for Halneuron® at an appropriate time, prioritizing funding based on various research projects[4] Employee and Operational Costs - The total number of full-time employees increased to 1,932 as of December 31, 2023, with total employee costs, including director remuneration, amounting to HKD 1,130.4 million, a 9.2% increase from the previous year[14] - Employee costs for 2023 totaled HKD 1,130.4 million, an increase of 9.1% from HKD 1,035.6 million in 2022[35] - Other expenses in 2023 amounted to HKD 100,878,000 for clinical trials and laboratory costs, a decrease of 5.2% from HKD 106,729,000 in 2022[36] Financial Outlook and Governance - The company is optimistic about future profitability, anticipating benefits from potential interest rate reductions, although increased R&D spending may impact costs[10] - The board of directors did not recommend a final dividend for the year ending December 31, 2023, compared to a dividend of HKD 0.008 per share totaling HKD 76,889,000 in 2022[39] - The company did not engage in any significant purchases, sales, or redemptions of its listed securities during the year[45] - The annual general meeting for 2024 is scheduled for May 23, 2024[50]

Interim Report 2023 長 江 生 命 科 技 INTERIM REPORT 2023 CK Life Sciences Int'l., (Holdings) Inc. | --- | |-------| | | | | 2023 中期報告 | --- | --- | --- | |----------|----------------------------------|-------| | | | | | 提升 | | | | 美好生活 | | | | | | | | | （於開曼群島註冊成立的有限公司） | | (Incorporated in the Cayman Islands with limited liability) (Stock Code: 0775) （股份代號：0775） 此 二 零 二 三 年 度 中 期 報 告（ 英 文 及 中 文 版 ）（「 中 期 報 告 」）已 於 本 公 司 網 站 www.ck-lifesciences.com登載。凡選擇（或被視為已同意）瀏覽在本公司網站登載之公司通 訊（包括但不限於中期報告）以代替收取印刷本之股東，均可透過本公司股份登 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本文件的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本文件全 部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 (於開曼群島註冊成立之有限公司) (股份代號：0775) 二零二三年中期業績 二零二三年中期業績 截至二零二三年六月三十日止六個月，長江生命科技集團有限公司（「長江生命 科技」或「公司」）錄得未經審核股東應佔溢利約港幣三千七百萬元，較去年同 期下跌百分之四十三。 | --- | --- | |--------------------------------------------------------------|----------------------------------------------------------------------| | | | | | 二零二三年上半年之整體溢利因加息導致財務成本高企而大幅受壓。在營運層 | | 面，農業相關業務及保健產品業務實質錄得較二零二二年為佳之業績 | — 溢利 | | | 比對去年同期上升百分之二十二。惟有關增幅被全數抵銷仍不足以彌補加 ...

長 江生命科技 2022年報 | --- | --- | --- | |------------------|-------|------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | | | | | 提升美好生活 | | | | | | | | | | CK Life Sciences Int'l., (Holdings) Inc. 長 江 生 命 科 技 集 團 有 限 公 司 (於開曼群島註冊成立的有限公司) | (股份代號：0775) 長 江生命科技 ■9 長 江 生 命 科 技 集 團 有 限 公 司 於 香 港 聯 合 交 易 所 有 限 公 司 上 市 。 本著提升人類生活質素之使命,長江生命科技從事產品之 研發、製造、商品化、推廣、銷售及投資,涉及的項目和資產 涵 蓋 保 健 、醫 藥 及 農 業 相 關 業 務 三 大 範 疇 。 長 江 生 命 科 技 為 長江和記實業集團 ...